Aflac (AFL) Aandelenoverzicht
Aflac Incorporated biedt via haar dochterondernemingen aanvullende ziektekosten- en levensverzekeringsproducten aan. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 3/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 5/6 |
AFL Community Fair Values
Create NarrativeSee what 62 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aflac Incorporated Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$113.60 |
| 52 Week Hoogtepunt | US$119.32 |
| 52 Week Laag | US$96.95 |
| Bèta | 0.62 |
| 1 maand verandering | 2.79% |
| 3 maanden verandering | -3.03% |
| 1 Jaar Verandering | 6.87% |
| 3 jaar verandering | 70.39% |
| 5 jaar verandering | 104.68% |
| Verandering sinds IPO | 190,891.78% |
Recent nieuws en updates
Seeking Alpha • May 06
Aflac: An Insurer To Buy After Impressive Q1 Results, Even As Valuation Rises
Summary Aflac remains a Buy despite a Q1 earnings miss, supported by organic policy growth, proven dividend increases, and robust balance sheet strength. Growth catalysts include new policy sales, expanding Asian market presence, and niche segments like pet insurance, though revenue trends remain uneven. Margins and expense ratios are favorable, with A-level credit ratings and conservative leverage, but forward P/E multiples signal some overvaluation and more muted near-term upside. Dividend growth (+16% YoY) and a low payout ratio (~30%) reinforce AFL's appeal for income investors, while technicals support a bullish trend as well after a recovery signal. Read the full article on Seeking Alpha
Analyse-update • May 01
AFL: Future Returns Will Balance Reinsurance Moves With Cautious Earnings Expectations
Narrative Update on Aflac The consensus analyst price target for Aflac has edged lower by a few dollars to $111.86, as analysts factor in more cautious revenue growth assumptions alongside slightly stronger profit margin and future P/E inputs. Analyst Commentary Recent research on Aflac reflects a mixed but mostly cautious tone, with several firms trimming price targets by small amounts and one lifting its target and reinitiating coverage at a neutral stance.Analyse-update • Apr 17
AFL: Future Returns Will Reflect Mixed Earnings Outlook And Product Expansion
Aflac's updated fair value estimate has been trimmed from $113 to about $111.86 as analysts consolidate mixed price target moves. This reflects slightly softer assumptions on revenue growth, profit margins, and future P/E while still seeing support from recent target adjustments across major firms.Recent updates
Seeking Alpha • May 06
Aflac: An Insurer To Buy After Impressive Q1 Results, Even As Valuation Rises
Summary Aflac remains a Buy despite a Q1 earnings miss, supported by organic policy growth, proven dividend increases, and robust balance sheet strength. Growth catalysts include new policy sales, expanding Asian market presence, and niche segments like pet insurance, though revenue trends remain uneven. Margins and expense ratios are favorable, with A-level credit ratings and conservative leverage, but forward P/E multiples signal some overvaluation and more muted near-term upside. Dividend growth (+16% YoY) and a low payout ratio (~30%) reinforce AFL's appeal for income investors, while technicals support a bullish trend as well after a recovery signal. Read the full article on Seeking AlphaAnalyse-update • May 01
AFL: Future Returns Will Balance Reinsurance Moves With Cautious Earnings Expectations
Narrative Update on Aflac The consensus analyst price target for Aflac has edged lower by a few dollars to $111.86, as analysts factor in more cautious revenue growth assumptions alongside slightly stronger profit margin and future P/E inputs. Analyst Commentary Recent research on Aflac reflects a mixed but mostly cautious tone, with several firms trimming price targets by small amounts and one lifting its target and reinitiating coverage at a neutral stance.Analyse-update • Apr 17
AFL: Future Returns Will Reflect Mixed Earnings Outlook And Product Expansion
Aflac's updated fair value estimate has been trimmed from $113 to about $111.86 as analysts consolidate mixed price target moves. This reflects slightly softer assumptions on revenue growth, profit margins, and future P/E while still seeing support from recent target adjustments across major firms.Analyse-update • Apr 03
AFL: Future Returns Will Reflect Capital Strength And Earnings Execution Risks
Narrative Update The analyst price target framework for Aflac now centers around $113. This reflects updated Street work, with some firms raising targets toward $118 and others trimming into the $101 to $120 range as analysts refresh earnings estimates and extend their valuation horizons.Analyse-update • Mar 20
AFL: Future Returns Will Balance Cybersecurity Fallout And Capital Strength
Narrative update on Aflac The analyst price target framework for Aflac shifts modestly higher toward the recent Street range, reflecting updated EPS roll forward work, a slightly adjusted future P/E assumption to 16.36x, and analysts' mixed but constructive views that blend a higher $118 target with several reductions closer to $101 to $120. Analyst Commentary Recent research on Aflac is mixed, with some bullish analysts nudging targets higher while more cautious voices trim expectations.Analyse-update • Mar 05
AFL: Future Returns Will Weigh Cyber Breach Risks Against Capital Strength
Aflac's updated analyst price target edges higher to about $113, supported by analysts rolling their models to 2027 and 2028 EPS and fine tuning assumptions around slightly stronger profit margins and a modestly lower future P/E multiple. Analyst Commentary Recent Street research on Aflac highlights a mix of optimism and caution as analysts update their models and valuation frameworks out to 2027 and 2028.Analyse-update • Feb 19
AFL: Future Returns Will Balance Cyber Risk And Capital Strength
Analysts now see Aflac's fair value edging up by $1 to $111.69 per share, reflecting adjusted price targets that factor in updated views on revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bullish and cautious voices are both active around Aflac right now, with recent price target trims reflecting fine tuning of expectations rather than a wholesale shift in views on execution or valuation.Analyse-update • Feb 05
AFL: Future Returns Will Reflect Capital Strength Versus Cyber And Insurance Headwinds
Narrative Update: Aflac The analyst price target for Aflac has been trimmed slightly, with a new fair value estimate of about $110.69 compared with $110.85 before. Analysts are factoring in updated sector views on life and P&C insurers, modest tweaks to revenue growth and margin assumptions, and only a small adjustment to future P/E expectations.Analyse-artikel • Jan 30
Aflac's (NYSE:AFL) Dividend Will Be Increased To $0.61
Aflac Incorporated ( NYSE:AFL ) has announced that it will be increasing its dividend from last year's comparable...Analyse-update • Jan 21
AFL: Future Returns Will Balance Capital Strength With Cyber And Sector Headwinds
Narrative Update on Aflac Aflac's updated analyst price target edges lower to about $111, as analysts moderate expectations for revenue growth and margins while still citing capital strength, cash flow, and sector consolidation as key supports. Analyst Commentary Recent research on Aflac reflects a mix of optimism about capital strength and cash flow, alongside caution around industry headwinds and valuation expectations.Analyse-update • Jan 06
AFL: Future Returns Will Reflect Stable Earnings Power And Capital Returns Balancing Cyber Risks
Analysts made only a small adjustment to their Aflac fair value estimate, with the target price moving from about $111.08 to $111.31 as they factor in recent price target revisions across the sector, softer pricing trends in some insurance lines, and generally steady modeling updates following calm recent earnings seasons. Analyst Commentary Street research around Aflac reflects a mix of optimism on company specific execution and caution around broader insurance pricing trends, which feeds into relatively modest adjustments to fair value estimates.Analyse-update • Dec 15
AFL: Future Performance Will Reflect Claims Tailwinds And Balanced Capital Return Execution
Analysts have modestly raised their price targets on Aflac, with recent upward revisions ranging from approximately $5 to $6 per share. They cite better than expected life insurance earnings, favorable claims experience, and resilient earnings trends despite macro uncertainties.Analyse-update • Dec 01
AFL: Future Performance Will Reflect Strength In Claims And Distribution Execution
Aflac's analyst price target increased modestly, with recent updates reflecting improved life insurance earnings and stable macro conditions as key factors cited by analysts. Analyst Commentary Recent updates from street research highlight several factors influencing Aflac's valuation targets, with analysts weighing both potential growth drivers and areas of caution.Analyse-artikel • Nov 18
Aflac's (NYSE:AFL) Dividend Will Be $0.58
The board of Aflac Incorporated ( NYSE:AFL ) has announced that it will pay a dividend on the 1st of December, with...Analyse-update • Nov 16
AFL: Future Earnings Outlook Will Reflect Improving Claims And Distribution Strength
The analyst price target for Aflac has increased modestly, with a $1 uptick in fair value to $111.00. Analysts point to stable industry conditions and improving claims experience supporting the outlook.Analyse-update • Nov 01
AFL: Earnings Stability And Strong Buybacks Will Support Balanced Outlook
Analysts have increased their price targets for Aflac, with upward revisions ranging from $1 to $6 per share. They cite stable earnings performance, as well as positive impacts from new product sales and favorable claims experience.Analyse-update • Oct 18
Custom Cancer Insurance And Digital Underwriting Will Drive Future Expansion
Aflac's analyst price target has been increased from $108.31 to $110.00. Analysts cite steady improvements in revenue growth, profit margins, and favorable claims experience as key factors supporting the upward revision.Analyse-update • Oct 04
Custom Cancer Insurance And Digital Underwriting Will Drive Future Expansion
Aflac's analyst price target has been raised slightly, with an increase of $2 to $108. Analysts highlight strong Q2 sales driven by new product rollouts and improved net interest income.Seeking Alpha • Jan 08
Aflac's Shares Are Overvalued
Summary Aflac Incorporated's heavy reliance on Japan, a market with weak long-term growth prospects, leads to relatively muted growth and significant currency risk exposure. Despite its strong financial position, Aflac's premium valuation compared to peers is unjustified given its average earnings momentum and low dividend yield. Aflac's strategy focuses on attracting younger customers in Japan but faces structural challenges due to the country's aging and shrinking population. For long-term investors, Manulife offers a better risk-reward proposition in the insurance sector compared to Aflac. Read the full article on Seeking AlphaSeeking Alpha • Nov 02
Insurer Aflac Quacks Away At Policy Growth And Low Debt Risk
Summary Aflac gets upgraded to Buy from my prior hold rating a year ago, driven by policy growth & retention in Q3 despite net earnings loss. Although the stock trades near a 10-year-high, it is still undervalued to key peers in terms of fwd P/E and trailing P/B ratios. A trend of dividend growth looks to continue its sustainability. The firm has low debt-to-equity vs peers, with strong credit ratings. Despite a large size of the market, Aflac is in a competitive industry with several large insurance brands to compete with. Read the full article on Seeking AlphaSeeking Alpha • Aug 26
Aflac: Double Digit Dividend Growth And Strong Portfolio Of Investments
Summary Aflac (AFL) has demonstrated financial strength through its increased revenue, net investment gains, and decreased benefits and claims. The current dividend yield remains modest at 1.8% but the dividend growth rate sits in the double digits. This is accompanied by an extremely health payout ratio. AFL's portfolio of debt investments, including middle market loans and commercial real estate, has helped generate higher revenues, but vulnerability exists with potential interest rate cuts and poor credit ratings. Read the full article on Seeking AlphaSeeking Alpha • Apr 22
Aflac Incorporated: Good Positioning But Risks From Japan
Summary Aflac recently reached its all-time high price, but has been showing signs of uncertainty lately. The company possesses a strong business foundation, poised to sustain a steady level of revenue in the foreseeable future, but exposure to macroeconomic scenarios creates uncertainty. I think it would be wise to hold off for now and monitor how the company adapts to the macroeconomic environment. There’s a chance we could buy in at a lower price later on. Read the full article on Seeking AlphaSeeking Alpha • Apr 09
Aflac: Growing Cancer Cases Will Lead To Higher Revenues
Summary Aflac remains a strong dividend-growth company, with a history of increasing dividends for 41 consecutive years. Cancer insurance sales are expected to be a major catalyst for long-term growth in both the Japanese and US markets. Despite missing revenue expectations in the latest earnings report, AFL's financials and outlook remain positive, with a focus on reducing expenses and increasing margins to mitigate short-term decreases. The dividend has grown at a double-digit CAGR over the last five-year period. Read the full article on Seeking AlphaRendement voor aandeelhouders
| AFL | US Insurance | US Markt | |
|---|---|---|---|
| 7D | -0.06% | -1.3% | 2.1% |
| 1Y | 6.9% | -10.0% | 30.6% |
Rendement versus industrie: AFL overtrof de US Insurance industrie, die het afgelopen jaar een rendement -10 % opleverde.
Rendement versus markt: AFL presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.6 % opleverde.
Prijsvolatiliteit
| AFL volatility | |
|---|---|
| AFL Average Weekly Movement | 2.4% |
| Insurance Industry Average Movement | 4.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: AFL heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 2% ) van AFL is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1955 | 12,716 | Dan Amos | www.aflac.com |
Aflac Incorporated biedt via haar dochterondernemingen aanvullende ziektekosten- en levensverzekeringsproducten aan. Het is actief in twee segmenten, Aflac Japan en Aflac U.S. Het segment Aflac Japan biedt kanker-, medische, verpleegzorg-, levensverzekerings- en GIFT-verzekeringsproducten, evenals WAYS- en kinderfondsverzekeringsproducten en Tsumitasu-verzekeringsproducten in Japan.
Aflac Incorporated Samenvatting
| AFL fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$57.72b |
| Inkomsten(TTM) | US$4.64b |
| Inkomsten(TTM) | US$18.11b |
12.5x
Koers/Winstverhouding3.2x
P/S-verhoudingIs AFL overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AFL resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$18.11b |
| Kosten van inkomsten | US$9.05b |
| Brutowinst | US$9.07b |
| Overige uitgaven | US$4.43b |
| Inkomsten | US$4.64b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
Aug 06, 2026
| Winst per aandeel (EPS) | 9.11 |
| Brutomarge | 50.05% |
| Nettowinstmarge | 25.60% |
| Schuld/Eigen Vermogen Verhouding | 48.0% |
Hoe presteerde AFL op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
2.1%
Huidig dividendrendement27%
UitbetalingsratioBetaalt AFL een betrouwbaar dividend?
Zie AFL dividendgeschiedenis en benchmarks| Aflac dividenddata | |
|---|---|
| Ex Dividend Datum | May 20 2026 |
| Betaaldatum dividend | Jun 01 2026 |
| Dagen tot Ex-dividend | 10 days |
| Dagen tot dividendbetaaldatum | 22 days |
Betaalt AFL een betrouwbaar dividend?
Zie AFL dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/07 15:07 |
| Aandelenkoers aan het einde van de dag | 2026/05/07 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Aflac Incorporated wordt gevolgd door 30 analisten. 9 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jay Gelb | Barclays |
| Taylor Scott | Barclays |
| Jack Matten | BMO Capital Markets Equity Research |